RxDoctor Payments Data

Kimi Guffey

Primary Care · Bristol, TNNPI 1023336708

Payments from drug & device makers

$909in general payments, 2019–2025

Across 22 payments — averaging $41.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$397
  • AbbVie$185
  • Lilly USA, LLC$140
  • Novo Nordisk$134
  • Pfizer$24
  • Xeris Pharmaceuticals, Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$909 in reported general payments places this provider in the 60th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$17,140
Medicare patients
68
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$77,465
JardianceEmpagliflozin47$44,954
EliquisApixaban51$41,232
VraylarCariprazine Hcl25$40,401
OzempicSemaglutide33$40,345
TrulicityDulaglutide33$32,202
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$30,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,249
JanuviaSitagliptin Phosphate31$24,353
XareltoRivaroxaban30$23,729
QuliptaAtogepant14$17,805
FarxigaDapagliflozin Propanediol13$12,443
SymbicortBudesonide/Formoterol Fumarate47$12,206
Breo ElliptaFluticasone/Vilanterol25$10,260
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$7,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$140$109,66786 claims
AbbVieVraylar, Qulipta$185$58,20639 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$397$54,95998 claims
PfizerEliquis$24$41,23251 claims
Novo NordiskOzempic$134$40,34533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 189 primary care providers in Tennessee.

Other primary care in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →